Kombiglyze XR now available

PRINCETON, N.J. — A new oral treatment for Type 2 diabetes hit the shelves Friday.

Bristol-Myers Squibb and AstraZeneca announced the availability of Kombiglyze XR (saxagliptin and metformin hydrochloride), which the companies called the only once-daily treatment for diabetes that combined metformin with a DPP-4 inhibitor, the drug class to which saxagliptin belongs.

The drug is designed for use alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes.